LU LUPIN
Lupin Q2 2027
LULUPIN

Lupin Q2 FY27 results (Jul–Sep 2026) and concall

Healthcare · Concall AI · Call held 4 Nov 2026

Management summary

  • Lupin delivered a steady Q2 FY27 with 11% YoY revenue growth to ₹7,827 crores, anchored by solid performance in India (+14.7% YoY) and Other Developed Markets (+46% YoY).
  • However, profitability faced pressure as EBITDA margin dropped to 25.1% from 31.3% last year due to intensifying generic competition in Tolvaptan in the US and higher operating expenses.
  • The company maintained its full-year FY27 guidance of USD 1.1-1.2 billion for US revenue and 24-25% EBITDA margin.
  • Upcoming complex generics, 505(b)(2) launches like Apixaban, and biosimilars..

Source: Inve concall analysis and management guidance record.

Highlights

  • Total revenues from operations grew 11% YoY to ₹7,827 crores from ₹7,048 crores in Q2 FY26

  • India formulation business grew 14.7% YoY, with chronic therapies growing 19.5% in H1 and accounting for 66% of portfolio mix

  • Other Developed Markets (Europe, Canada, Australia) grew 46% YoY to ₹1,182 crores, contributing 15% of total revenues

  • Gross margin improved to 74.2% compared to 73.3% in Q2 FY26

What they filed

Q2 FY27: revenue down 12.3%, net profit down 100.4% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue4,208 4,486 5,709 4,068 4,501 +7%5,235 +17%7,172 +26%3,567 −12%
EBITDA1,411 1,746 2,730 1,176 1,617 +15%2,282 +31%3,733 +37%211 −82%
Net profit985 1,291 2,128 1,357 717 −27%2,164 +68%2,715 +28%-6 −100%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • Ex-US Organic Revenue Growth Revenue · H2 FY27 · High confidence around 20%

Margin

  • EBITDA Margin Margin · FY27 · High confidence 24–25%

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

2 direct
Tolvaptan and Mirabegron Impact on Gross Margins and Share Direct
We had market share of 50% in the last couple of months, being the sole generic in the marketplace. With this additional competition, obviously, we will be giving up some share. The bigger impact is on pricing... margin contribution and revenue contribution to come down significa

Tolvaptan exclusivity was a huge profit driver; entry of 2 generic players and more expected will cause meaningful price erosion and margin drag.

Asked by Dhara Ganatra / Neha Manpuria

Apixaban Oral Suspension 505(b)(2) Launch & Commercial Strategy Direct
We expect to launch the product in the first quarter of FY28, and as we gain traction in the channels that we have targeted, we expect the share to build up... We are expecting a margin like an exclusive product, but with some investment on the commercial front.

Apixaban oral suspension tentative approval represents a critical FY28 growth catalyst to offset Tolvaptan and Mirabegron LOEs.

Asked by Shashank Krishnakumar / Neha Manpuria / Rashmi Shetty

Unlock risks & concerns, Q3 FY27 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 8 risks, concerns & management red flags
  • 4 watchlist triggers for Q3 FY27
  • +11 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image